Journal
MOVEMENT DISORDERS
Volume 24, Issue 3, Pages 392-400Publisher
WILEY-LISS
DOI: 10.1002/mds.22357
Keywords
Parkinson's disease dementia; dementia with Lewy bodies; apolipoprotein E; butyrylcholinesterase
Categories
Funding
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Novartis
- Medical Research Council [G0502157, G0400074] Funding Source: researchfish
- MRC [G0502157, G0400074] Funding Source: UKRI
Ask authors/readers for more resources
Apolipoprotein E (APOE) epsilon 4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample. associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE epsilon 4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other enotypes. Subjects with hyperhomo-cysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE epsilon 4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders. (C) 2008 Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available